Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
2.
Paediatr Respir Rev ; 34: 24-34, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32247829

RESUMEN

PURPOSE: The objective of this study was to describe the diagnostic yield and safety of bronchoalveolar lavage (BAL) in the evaluation of pulmonary lesions in immunocompromised children. METHODS: We conducted a systematic review of literature published during the past 20 years, searching Medline, Medline EPub, EMBASE, and Scopus. Studies included involved paediatric patients (<18 years) on treatment for an oncological diagnosis or other immune compromise who underwent BAL for evaluation of pulmonary lesions. Only English language publications were included. RESULTS: In all, 272 studies were screened and 19 included. All were observational studies with moderate (11/19) or serious (8/19) risk of bias. BAL yielded a potential pathogen in 43% of cases (496/1156). Two papers reported improved diagnostic yield with early BAL (less than 3 days of presentation). A change in patient management after BAL was reported in 53% of cases (275/519). Adverse events were reported in 19% of cases following BAL (193/993) but were generally mild with no procedure-related mortality reported. CONCLUSION: BAL appears to be useful for evaluation of pulmonary lesions in immunocompromised children with generally acceptable safety, though included studies had at least moderate risk of bias. Future prospective studies may provide more definitive estimates of benefit, timing and risk of BAL in this population.


Asunto(s)
Broncoscopía , Huésped Inmunocomprometido , Enfermedades Pulmonares Fúngicas/diagnóstico , Neumonía Bacteriana/diagnóstico , Neumonía Viral/diagnóstico , Antiinfecciosos/uso terapéutico , Lavado Broncoalveolar , Líquido del Lavado Bronquioalveolar , Niño , Sustitución de Medicamentos , Humanos , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Enfermedades Pulmonares Fúngicas/inmunología , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/inmunología , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/inmunología
3.
Australas J Dermatol ; 55(3): 209-11, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24628677

RESUMEN

Questions have been raised as to whether propranolol, which crosses the blood-brain barrier, when used early in life may have an adverse effect on gross motor development. A retrospective survey asking questions about gross motor development was sent to the families of children who had been prescribed oral propranolol for infantile haemangioma at Sydney Children's Hospital between 2008 and 2013. It was found that of the 84 patients surveyed, four were delayed in walking unassisted. There was a statistically significant influence if the child was taking other medications which included prednisolone, vincristine, omeprazole, ranitidine, salbutamol, Flixotide, Timoptol and antibiotics. This was not further analysed in this study because of the low numbers involved. There was no statistically significant influence of gestational age, birth weight or length of time on propranolol. This study adds to the retrospective data available; however large-scale prospective studies are needed to identify unexpected long-term side-effects.


Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Desarrollo Infantil/fisiología , Hemangioma Capilar/tratamiento farmacológico , Propranolol/uso terapéutico , Neoplasias Cutáneas/tratamiento farmacológico , Desarrollo Infantil/efectos de los fármacos , Estudios de Seguimiento , Hospitales Pediátricos , Humanos , Lactante , Destreza Motora , Nueva Gales del Sur , Estudios Retrospectivos , Caminata
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...